Methodological Note - 2021
Accompanying document for the public disclosure concerning Transparency of Transfer of Value to Healthcare Professionals and Healthcare & Patient Organizations

Takeda Pharma Vertrieb GmbH & Co. KG & Takeda GmbH
Issue Date: 27.06.2022
Methodological Note 2021

1. General Introduction ........................................................................................................................................... 3
2. Scope of Disclosure ............................................................................................................................................. 3
   2.1 Recipient Scope ............................................................................................................................................... 3
      2.1.1 Healthcare Professionals (HCP): Definition and Scope ........................................................................... 3
      2.1.2 Healthcare Organizations (HCO): Definition and Scope ....................................................................... 3
      2.1.3 Patient Organizations (PtO): Definition and Scope ............................................................................. 4
      2.1.4 Companies Owned by a Healthcare Professional .................................................................................... 4
      2.1.5 Clearly Identifiable Recipient .............................................................................................................. 4
      2.1.6 Third Party and Professional congress organiser (PCO) ......................................................................... 4
   2.2 Medicinal Scope .............................................................................................................................................. 4
   2.3 Scope regarding Transfer of Value activities ................................................................................................. 4
      2.3.1 Grants and Donations to Healthcare Organizations (HCO) or Patient Organizations (PtO) .................... 5
      2.3.2 Contributions to Costs of Events ............................................................................................................ 5
      2.3.3 Fees for Services and Consultancy ......................................................................................................... 5
      2.3.4 Research & Development ..................................................................................................................... 6
   2.4 Transfer of Value in Cross-Border Interactions .............................................................................................. 7
3. Private Consent to Disclosure and Aggregate Amount ......................................................................................... 7
   4.1 Date of Transfer of Value ............................................................................................................................... 8
   4.2 Currency ........................................................................................................................................................ 8
   4.3 Taxes .............................................................................................................................................................. 8
   4.4 Value-Added Tax (VAT) ............................................................................................................................... 9
5. Other General Provisions ...................................................................................................................................... 9
   5.1 Duration of Disclosure ................................................................................................................................... 9
   5.2 Clearing Institution / Dispute Resolution Management .................................................................................. 9
1. General Introduction

The collaboration between industry and health professionals is beneficial to patients. This relationship has delivered numerous innovative medicines and has changed the way many diseases affect our lives. Industry and health professionals collaborate in a wide range of activities, starting from clinical research and sharing best clinical practice up to the exchange of information on how new medicines fit into the patient pathway. Greater transparency in this already well-regulated relationship should help to create a stable foundation for future collaboration. Society has ever-increasing expectations regarding transparency, especially in the healthcare sector. As a member of the European Federation of Pharmaceutical Industries Associations ("EFPIA"), we aim to ensure that we meet these expectations in the future.

This methodological note is intended for all those who wish to better understand the assumptions behind the creation of the disclosure report of Takeda (includes Takeda Pharma Vertrieb GmbH & Co.KG and Takeda GmbH) and how the disclosed activities are defined within Takeda.

2. Scope of Disclosure

In order to correctly define what is to be regarded as a reportable Transfer of Value (ToV) operation according to the applicable EFPIA guidelines (https://efpia.eu/relationships-code/healthcare-professionals-hcps/) and to the requirements of the industrial associations relevant for the company Takeda in the Federal Republic of Germany, i.e. the Code of Transparency of the Association of Voluntary Self-Control of the Pharmaceutical Industry (Verein Freiwillige Selbstkontrolle für die Arzneimittelindustrie – FSA) for the interaction with Healthcare Professionals and Healthcare Organizations, as well as Patient Organizations ("FSA Transparency Code") (www.fsa-pharma.de) and the German Association of Research-Based Pharmaceutical Companies (Verband forschender Arzneimittelunternehmen, VfA) (www.vfa.de), various internal interpretations were required.

We have summarized below our interpretations and working assumptions which we consistently applied while gathering data, what the term "covered recipients" means for us and what exactly are the recipients, activities and expenses that are covered within the scope according to our definitions.

2.1 Recipient Scope

2.1.1 Healthcare Professionals (HCP): Definition and Scope

In the disclosure report, we considered the definitions established in line with the FSA code with regard to those healthcare professionals with whom our company may conduct Transfer of Value (ToV) transactions. In this context, the category of healthcare professionals includes any full-time physicians and pharmacists located in Europe, as well as any healthcare professionals from the medical, dental and pharmaceutical field or from any other kind of healthcare-related sectors, and any other kind of individuals who, within the framework of their professional activities, are entitled to prescribe or administer any medicinal products for human use or to trade in this kind of pharmaceutical products. This category also covers and comprises, for example, any employees of public institutions, health insurance companies and other kinds of cost units that are responsible for or in charge of prescribing, purchasing, supplying or administering any medicinal products or who are entitled to decide on the reimbursability of such products. The published address in the disclosure report will be the primary practice address of the respective HCP.

2.1.2 Healthcare Organizations (HCO): Definition and Scope

In the disclosure report, we considered the definitions established in line with the FSA code with regard to those healthcare organizations with whom our company may conduct Transfer of Value (ToV) transactions. Any kind of medical or scientific institutions or associations located in Europe and consisting of healthcare professionals are to be considered healthcare organizations, regardless of their respective legal structure; such organizations include the following: associations, hospital federations, hospital departments, care
education centers, clinics, dental clinics, dispensaries, institutions, faculties, universities, academic schools, foundations, pools or groupings of pharmacies, healthcare institutions). The published address in the disclosure report will be the public address of the respective HCO.

2.1.3 Patient Organizations (PtO): Definition and Scope
In the disclosure report, we considered the definitions established in line with the FSA code with regard to those patient organizations with whom we may conduct Transfer of Value (ToV) transactions. “Patient organizations” are voluntary, non-profit organizations of patients and/or their families, whose activities involve group support in coping with diseases, disseminating information about diseases and therapy options, lobbying in healthcare and social policy, publishing of media to inform and support patients and/or providing advisory services. "Representatives of patient self-help organisations" are persons who, on behalf of a patient organisation, represent it and express their views on a specific therapeutic area or on a specific issue.

2.1.4 Companies Owned by a Healthcare Professional
In case a Transfer of Value (ToV) made in favor of a company (HCO) can be indirectly assigned to one HCP, it would be subject to the requirements in the code regarding the disclosure of this ToV to that individual HCP. If, however, the company is owned by more than one HCP, the Transfer of Value is reported and disclosed in favor to an HCO.

2.1.5 Clearly Identifiable Recipient
Takeda has put in place an internal process in order to ensure that Transfers of Value are allocated to the proper HCP or HCO or PtO, and to make sure that the disclosed information is accurate and complete (e.g. name, address, country of primary practice). Takeda relies on IQVIA (formerly IMS Health & Quintiles), a leading provider of data management services, to ensure that primary practice addresses for healthcare professionals and health care organizations are consistent across EFPIA member countries. There may be deviations in the addresses recorded in the contract, in our financial payment system or in our supporting documentation. Healthcare Professionals (HCP) who acted for Takeda in 2021 but have since been inactivated in their status by IQVIA, will nevertheless be disclosure according to their consent at Takeda.

2.1.6 Third Party and Professional congress organiser (PCO)
Third parties are entities or individuals that represent our company in the marketplace or interact with other third parties on behalf of our company or relating to our company’s product. Among others, these third parties can be distributors, travel agents, consultants, contracted research organisations.

Professional congress organiser (PCO), or professional conference organiser, is a company/individual specialized in the organisation and management of congresses, conferences, seminars, and similar events (all “Events”).

2.2 Medicinal Scope
This report covers any kind of interactions with HCPs and HCOs/PtOs, irrespective of whether the collaboration relates to any prescription drugs or to over-the-counter (non-prescription) products.

2.3 Scope regarding Transfer of Value activities
The definitions of the activities can differ from one company to the next. Within Takeda, all our interactions with healthcare professionals (HCPs) are governed by internal policies and Standard Operating Procedures (SOPs) that have been developed in accordance with industry codes and guidelines and which are in line with local country-specific laws and regulations as well as with local industry requirements. Below you will find our corporate definitions which should help you with the readability of the disclosure report.
2.3.1 Grants and Donations to Healthcare Organizations (HCO) or Patient Organizations (PtO)

Any kind of Transfers of Value regarding a donation or a grant between Takeda and a HCO or PtO are included in the scope of the disclosure. These Transfers of Value could be, for instance, the following:

i. Donations (monetary);
ii. Charitable contributions (if the organization is classified as HCO or PtO in the country);
iii. Medical educational grants or contributions (e.g. supporting HCPs education): Such grants could be monetary in nature, e.g. IIIRSs, defined as unsolicited, independent research where the investigator or the institution (academic, private or governmental) serves as the sponsor and Takeda provides support in the form of study drugs and/or funding. Non-monetary nature (e.g., benefits in kind such as anatomic models).
iv. Non-medical educational training (e.g. support for healthcare institutions to improve their infrastructure)

2.3.2 Contributions to Costs of Events

Any kind of Transfers of Value in connection with a contribution to costs of events between Takeda and a HCP (directly or indirectly via a third party) or a HCO-/PtO Representative are included in the scope of the disclosure. Such Transfers of Value (for example those granted in connection with the participation in any congresses, conferences, symposia etc. which have a medical and scientific emphasis and which serve as educational event for HCPs) could be, for instance, the following:

i. Travel expenses (expenses for flight tickets/railway tickets, use of private car, taxi use, use of rental cars, parking fees);
ii. Accommodation costs;
iii. Registration fees (fees paid to permit HCPs or HCO-/PtO Representatives to attend medical/educational events organized by third party but not organized by Takeda);
iv. Sponsorship agreements with a HCO, PtO or a third party nominated by the HCO or PtO to manage and organize an event, such as third party scientific conferences, congresses or exhibits: sponsorships via medical societies; national industry organizations; hospitals and teaching institutions; scientific organizations; regional, national, international and global conferences; local hospitals; medical centres.

In case a scientific event is organized by an event planning agency and the non-cash grant is made to this agency – with this respective event having a clearly recognizable reference to a HCO or PtO – then the disclosure will be made by mentioning the event planning agency involved, including a corresponding declaration incorporated in this Methodological Note as to the purpose of use of that Transfer of Value.

Whenever a HCP or HCO-/PtO Representative who is sponsored in order to attend a third party meeting had to cancel his/her participation, this information as well as any information on any cancellation fees incurred will not be included in our report.

Examples of activities that may be covered in the Takeda disclosure report under the category of "Sponsorship Agreement" may be the following: rental of booth, rental of advertisement space (electronic, paper, etc.), participation in satellite symposia at a scientific congress, scientific courses provided by a HCO, opportunities to promote our products.

2.3.3 Fees for Services and Consultancy

Any Transfers of Value related to services and consultancy between Takeda and a HCP or a HCO-/PtO Representative are included in the scope of the disclosure. These Transfers of Value include, for example, any meetings or events (promotional or non-promotional) where the corresponding HCP or the HCP...
working for an HCO / PtO acts in the capacity of a speaker, trainer or advisor, and such Transfers of Value could be the following:

i. Fees (fees for services such as preparation time, rehearsal time, travel time and time required for the activity itself);

ii. Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract

Examples of fees that could be covered under the category of "Fees for Services & Consultancy (HCPs and HCOs / PtOs)" in the Takeda disclosure report may be the following: speaker fees for speaker programs and roundtables; ad-hoc consulting/advising arrangements; faculty for speaker training programs or training of Takeda employees or external parties; faculty for advisory board meetings; study participant for market research (only if no double-blinded research); medical writing; data analysis; development of educational material; market survey (only if not double-blinded survey); Non-interventional studies (retrospective); consultancy services (e.g. protocol-related advice, market access, indemnity payments).

2.3.4 Research & Development
Any Transfers of Value related to a Research and Development (R&D) activity are included in the scope of the disclosure. These include any Transfers of Value made to HCPs or HCOs in connection with the planning or conduct of:

iii. Any non-clinical trials intended to be submitted to regulatory authorities (as defined in the OECD principles on Good Laboratory Practice);

iv. Any clinical trials (as defined in the European Directive 2001/20/EC), namely
   a. Any clinical trials in humans using an unapproved medicinal product;
   b. Any clinical trials in humans using an approved medicinal product where it will be used for an unapproved indication or otherwise it will be prescribed outside the terms of its marketing authorization, or where patients are prospectively assigned to different treatments, or where the protocol requires any diagnostic or monitoring procedures which would not have been performed if the patient had not been included in the respective clinical trial;
   c. Any other type of clinical trials in humans for which a clinical trial approval from the regulatory authorities would be needed if the trial were to be conducted in the EU in line with the EU Directive 2001/20/EC;

v. Any prospective observational studies where the patient has received a prescription for an approved medicinal product and is treated with that medicinal product in accordance with the marketing authorization and the current practice as well as in accordance with the other requirements set out in section 15.01 of the EFPIA HCP Code;

vi. Any other kinds of activities such as:
   a. Any activities associated with the planning of patient recruitment and inclusion, of the design or timing of non-clinical studies, clinical trials and/or prospective observational studies within the context of a development plan for a particular medicinal product;
   b. Any activities associated with the planning of non-clinical studies, clinical trials or prospective observational studies;
   c. Any activities associated with the conduct of particular non-clinical studies, clinical trials or prospective observational studies.
Examples of activities that could be covered under the category “R&D Transfers of Value” in the Takeda disclosure report include the following: clinical trials: regional and/or global, local non-interventional studies.

The Transfers of Value made indirectly via a Clinical Research Organization (CRO) are also included in the R&D section of the disclosure report. Any payments made to CROs for CRO-specific services are not part of the disclosure report and will not be disclosed unless:

   i. the respective CRO is composed of HCPs or is associated with any medical institution (such as university hospitals or state-owned institutions). In this case, that CRO is considered an organization with any Transfer of Value operations being disclosed by us on an individualized basis in accordance with the general rules;
   
   ii. the respective CRO makes indirect Transfers of Value to HCPs (so-called “pass-through costs”). In this case, we will disclose such non-cash grants in an individualized way, specifying the corresponding HCP.

Any Transfers of Value related to R&D activities are reported as an aggregate total figure, with the exception of transfer of values related to retrospective, non-interventional studies, which shall comply with the provisions of Article 15 of the EFPIA HCP Code, which are disclosed by naming the individual recipient.

2.4 Transfer of Value in Cross-Border Interactions

Any Transfers of Value made in connection with cross-border interactions and activities are part of our disclosure report. The cross-border activities concerned are disclosed in the country of the HCP recipient’s primary practice address.

So if, for instance, a German HCP acting in the capacity of a consultant is contracted by a foreign Takeda legal entity, Takeda will disclose the associated Transfer(s) of Value in the disclosure report for Germany, in line with the respective HCP’s primary practice address.

3. Private Consent to Disclosure and Aggregate Amount

The HCP-related individual disclosure of the Transfers of Value provided to an HCP is covered and governed by local privacy regulations.

In Germany, the respective HCP should provide his/her privacy consent to allow the publication of the received Transfer of Value at an individual level. If such individual privacy consent is not provided, Takeda will publish the relevant Transfer of Value as an aggregate value including all HCPs who did not provide their privacy consent.

With regard the individual HCP-related disclosure, Takeda has decided to collect privacy consent for each Transfer of Value on the basis of which the respective HCP then agrees to the corresponding Transfers of Value being disclosed at an individual level. If, however, the HCP refuses to give his/her consent for at least one Transfer of Value, then all Transfers of Value operations related and made to this HCP will be disclosed as a total amount as well as on an aggregate basis and in an anonymized form.

If, for instance, a HCP is contracted for five individual activities throughout the year and gives his consent to disclosure for the first four of them and refuses to provide his consent for the last one, then all the related Transfers of Value will be disclosed in the aggregate section of the report on an aggregate basis and in an anonymized form.

A HCP may, at any moment, make use of his/her right to withdraw and revoke his/its consent for a given Transfer of Value. If such revocation is made before the official disclosure, then all Transfers of Value for
this particular HCP will be disclosed in the aggregate section of the report on an aggregate basis and in an anonymized form.

While respecting the local privacy legislation, Takeda has made the best efforts to obtain the privacy consents necessary to the disclosure of Transfer of Value transactions at the individual level and retains documented evidence regarding any request/receipt/denial of privacy consent.

4. Working Assumptions

4.1 Date of Transfer of Value

Within Takeda, each interaction with a Po, HCO and HCP is subject to a rigorous need assessment and to an internal approval process. Upon grant of approval, Takeda then proceeds to the contracting process which covers the Transfer of Value and the request for consent to disclosure, whenever relevant. The performance of service requested is tracked so that payments can be made according to the terms and conditions stipulated by contract.

In our country, we will use, based upon local industry, the date of service provision as basis for the recognition of the respective Transfer of Value.

By the “date of service provision”, we mean the date when the service was effectively rendered and delivered, which means, for example, that when a HCP participated in an Advisory Board Meeting, then the date when the Advisory Board effectively took place will be the date used for collecting all associated Transfers of Value (e.g. fees for services, travel cost), and the relevant information and data will be disclosed accordingly, even if some reimbursements will actually take place at a later stage.

Regarding to the cut-off rule we have established that the following shall apply:

If the date of service provision has taken place between January 1st and December 31st of the year 2021, the respective Transfer of Value transaction will be in scope for our 2021 disclosure report.

In addition, disclosure of Transfers of Value for a particular activity or service may also be done over a period of more than one year, considering the point in time at which the service was fully provided. It can also happen that some value transfers with an event date before 2021, but whose payment was not made until 2021 are therefore also published in 2021 (this applies in particular to former Shire transactions).

4.2 Currency

Takeda has adopted the currency EUR (euro) for the disclosure report, as this is - at the point of the disclosure- the official national currency. In the case a Transfer of Value is made in a currency other than the official local currency, the amount will be converted using the current exchange rates that are applicable at the time of service provision.

An example of a Transfer of Value made in a foreign currency would be when travel costs have incurred by a HCP in a foreign country where he/she delivers his/her service and we are reimbursing his/her transportation expenses.

4.3 Taxes

Any amounts paid are subject to taxes. The amounts captured in our report are net amounts which do not include VAT. However, these amounts are subject to income tax to be paid by the person in receipt of the benefit.
4.4 Value-Added Tax (VAT)
Any expenses such as travel or accommodation costs are subject to VAT. The data captured and disclosed do not include VAT.

4.5 Cancellation of events or contract cancellation
Takeda only allocates pecuniary benefits that are actually incurred and related to the HCP based on supporting documentation. In the circumstances when a flight or accommodation is booked, but the event is cancelled or the HCP does not attend, no ToV will be attributed to that HCP. Due to the COVID-19 developments in the year of publication 2021, any cancellation fees incurred for events that have been cancelled or not taken place will, however, be published.

5. Other General Provisions
This Methodological Note is in line with the basic principles of FSA, which can be found at www.pharma-transparenz.de

5.1 Duration of Disclosure
As a general rule, the disclosure report on Transfers of Value for the year 2021 will be accessible on our homepage for a period of three years. If a HCP revokes his/her consent to disclosure before the expiry of this period, we will adjust our report accordingly.

5.2 Clearing Institution / Dispute Resolution Management
Takeda has implemented a clearing institution in case of the occurrence of, for instance, any general questions and disagreements as far as any of the reported data and/or any requests for adding or removing a privacy consent given by a HCP/HCO/PtO to disclosed data are concerned; this clearing institution will be available for handling and clarifying any questions and inconsistencies that may arise.

If you have any comments or questions about Takeda's mode of processing of specific data and information, about this Methodological Note, about the content of the disclosure or about Takeda's internal Privacy Policy, please feel free to contact the corresponding persons regarding the FSA Transparency Code Takeda Transparency function using the e-mail address “transparenz@takeda.com” or the contact indicated on the Takeda website (https://www.takeda.com/de-de/unternehmerische-verantwortung/transparenz/).